Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	917	\$4amphetamine same (determin\$5 or detect\$3)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2005/05/23 15:19
L2	401	I1 and antibody	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	ÓR	OFF	2005/05/23 15:19
L3	273	I2 and link\$3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2005/05/23 15:21
L4	16	l3 and bivalent	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2005/05/23 15:22

10/806, 327

FILE 'HOME' ENTERED AT 14:23:23 ON 23 MAY 2005

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

=>

FILE 'REGISTRY' ENTERED AT 14:23:31 ON 23 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 MAY 2005 HIGHEST RN 850859-04-0 DICTIONARY FILE UPDATES: 22 MAY 2005 HIGHEST RN 850859-04-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*\*\*

\* The CA roles and document type information have been removed from \*

\* the IDE default display format and the ED field has been added, \*

\* effective March 20, 2005. A new display format, IDERL, is now \*

\* available and contains the CA role and document type information. \*

\* \*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

Uploading C:\Program Files\Stnexp\Queries\10806327.str

chain nodes : 7 8 9 10 11 12 17 18 26 27 29 14 15 16 ring nodes : 1 2 3 4 5 6 20 21 22 23 24 chain bonds : 4-14 6-7 7-8 8-9 8-12 9-10 9-11 14-15 15-16 16-17 16-36 17-18 18-23 21-26 26-27 27-28 27-30 28-29

ring bonds : 1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25 exact/norm bonds : 4-14 8-9 9-10 9-11 14-15 16-36 17-18 18-23 27-28 28-29 exact bonds : 6-7 7-8 8-12 15-16 16-17 21-26 26-27 27-30 normalized bonds :  $1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 5-6 \quad 20-21 \quad 20-25 \quad 21-22 \quad 22-23 \quad 23-24 \quad 24-25$ isolated ring systems : containing 1 : 20 :

G1:0,S


G2:Ak,H

# Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 36:CLASS

#### L1STRUCTURE UPLOADED

=> d 11L1 HAS NO ANSWERS L1 STR



G1 0, S G2 Ak,H

Structure attributes must be viewed using STN Express query preparation.

=> s 11SAMPLE SEARCH INITIATED 14:24:39 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 289 TO ITERATE

289 ITERATIONS 100.0% PROCESSED SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\* \*\*COMPLETE\*\* BATCH 4761 TO 6799 PROJECTED ITERATIONS:

PROJECTED ANSWERS:

0 TO

0

=> s li sss full 99643 LI 16507 LIS L3 116146 LI

(LI OR LIS)

=> s l1 sss full

FULL SEARCH INITIATED 14:25:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5455 TO ITERATE

100.0% PROCESSED 5455 ITERATIONS SEARCH TIME: 00.00.02

O ANSWERS

T.4

0 SEA SSS FUL L1

=> Uploading C:\Program Files\Stnexp\Queries\10806327b.str

chain nodes : 7 8 9 10 12 13 14 15 16 24 25 26 33 34 ring nodes : 1 2 3 4 5 6 18 19 20 21 22 23 chain bonds : 4-12 6-7 7-8 8-9 8-10 12-13 13-14 14-15 14-34 15-16 16-21 19-24 24-25 25-26 25-33 ring bonds : 1-2 1-6 2-3 3-4 4-5 5-6 18-19 18-23 19-20 20-21 21-22 22-23 exact/norm bonds : 4-12 8-9 12-13 14-34 15-16 16-21 25-33 exact bonds : 6-7 7-8 8-10 13-14 14-15 19-24 24-25 25-26normalized bonds :  $1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 5-6 \quad 18-19 \quad 18-23 \quad 19-20 \quad 20-21 \quad 21-22 \quad 22-23$ isolated ring systems : containing 1 : 18 :

G1:0,S

G2:Ak,H

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 25:CLASS 26:CLASS 33:CLASS 34:CLASS

=> d 15

L5 HAS NO ANSWERS

$$G1[CH_2]CH_5[CH_2]_1G_{\overline{5}}$$

G1 0, S

G2 Ak,H

Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 14:28:58 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 251 TO ITERATE

100.0% PROCESSED

251 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE

\*\*COMPLETE\*\*

\*\*COMPLETE\*\* BATCH 5970

PROJECTED ITERATIONS:

4070 TO

PROJECTED ANSWERS:

0 TO

L6

0 SEA SSS SAM L5

=> s 15 sss full

FULL SEARCH INITIATED 14:29:43 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 4599 TO ITERATE

100.0% PROCESSED 4599 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

L7

0 SEA SSS FUL L5

=> Uploading C:\Program Files\Stnexp\Queries\10806327c.str

chain nodes : 7 8 9 11 12 13 14 15 23 24 25 32 33 34 ring nodes : 1 2 3 4 5 6 17 18 19 20 21 22 chain bonds :  $4-11 \quad 6-7 \quad 7-8 \quad 8-9 \quad 8-32 \quad 11-12 \quad 12-13 \quad 13-14 \quad 14-15 \quad 15-20 \quad 18-23 \quad 23-24 \quad 24-25$ 24-34 32-33 ring bonds : 1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22 exact/norm bonds : 4-11 8-32 11-12 14-15 15-20 24-34 32-33 exact bonds : 6-7 7-8 8-9 12-13 13-14 18-23 23-24 24-25 normalized bonds :  $1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 5-6 \quad 17-18 \quad 17-22 \quad 18-19 \quad 19-20 \quad 20-21 \quad 21-22$ isolated ring systems : containing 1 : 17 :

G1:0,S


G2:Ak,H

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:CLASS 24:CLASS 25:CLASS 32:CLASS 33:CLASS 34:CLASS

L8 STRUCTURE UPLOADED

=> d 18 L8 HAS NO ANSWERS L8 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 18
SAMPLE SEARCH INITIATED 14:33:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 291 TO ITERATE

100.0% PROCESSED 291 ITERATIONS SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 4797 TO 6843
PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L8

=> s 18 sss full FULL SEARCH INITIATED 14:33:55 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 5472 TO ITERATE

100.0% PROCESSED 5472 ITERATIONS SEARCH TIME: 00.00.01

0 ANSWERS

L10 0 SEA SSS FUL L8

Uploading C:\Program Files\Stnexp\Queries\10806327d.str

CH2<sup>3</sup>0-14

CH2<sup>3</sup>0-14

NH223-22

15-16

15-16

15-16

17

19-18

NH223-22

chain nodes : 7 8 9 17 18 19 22 23 24 25 ring nodes : 1 2 3 4 5 6 11 12 13 14 15 16 chain bonds : 4-25 6-7 7-8 8-9 8-22 12-17 14-25 17-18 18-19 18-24 22-23 ring bonds : 1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 exact/norm bonds : 8-22 18-24 22-23 exact bonds : 4-25 6-7 7-8 8-9 12-17 14-25 17-18 18-19 normalized bonds : 1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 isolated ring systems : containing 1 : 11 :

G1:0,S

G2:Ak,H

Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS

=> d 111 L11 HAS NO ANSWERS L11 STR

Structure attributes must be viewed using STN Express query preparation.

=> s 111

SAMPLE SEARCH INITIATED 14:37:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 80 TO ITERATE

100.0% PROCESSED 80 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS:

1064 TO 2136

PROJECTED ANSWERS:

0 TO C

L12 0 SEA SSS SAM L11

=> s 112 sss full

FULL SEARCH INITIATED 14:37:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1862 TO ITERATE

100.0% PROCESSED 1862 ITERATIONS SEARCH TIME: 00.00.01

10 ANSWERS

bhrach linh. co.co.cl

L13 10 SEA SSS FUL L11

=> s 12 sss full

FULL SEARCH INITIATED 14:38:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5455 TO ITERATE

100.0% PROCESSED 5455 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.02

L14 0 SEA SSS FUL L1

=> s 16 sss full

FULL SEARCH INITIATED 14:38:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4599 TO ITERATE

100.0% PROCESSED 4599 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

=> s 19 sss full

FULL SEARCH INITIATED 14:39:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5472 TO ITERATE

100.0% PROCESSED 5472 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L16

0 SEA SSS FUL L8

=> s 111 sss full

FULL SEARCH INITIATED 14:40:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1862 TO ITERATE

100.0% PROCESSED 1862 ITERATIONS

10 ANSWERS

1304.48

SEARCH TIME: 00.00.01

L17

10 SEA SSS FUL L11

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 14:41:01 ON 23 MAY 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 May 2005 VOL 142 ISS 22 FILE LAST UPDATED: 22 May 2005 (20050522/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 113

L18

9 L13

=> d 118 ibib abs hitstr tot

L18 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

2005:324179 CAPLUS

DOCUMENT NUMBER:

142:411656

TITLE:

Synthesis of antibacterial biphenyl-containing

macrocycles for use in treating bacterial infections

in humans or animals

INVENTOR(S):

Lampe, Thomas; Adelt, Isabelle; Beyer, Dieter; Brunner, Nina; Endermann, Rainer; Ehlert, Kerstin; Kroll, Hein-Peter; Von Nussbaum, Franz; Raddatz, Siegfried; Rudolph, Joachim; Schiffer, Guido;

Schumacher, Andreas; Cancho-Grande, Yolanda; Michels,

Martin; Weigand, Stefan

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany

SOURCE: PCT Int. Appl., 181 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT	KIND DATE				1	APPL:	ICAT:	ION I	DATE						
WO 2005	0 2005033129						,	EP10	20040922						
W:	AE, AG,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
	CN, CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
	GE, GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	ΚZ,	LC,
	LK, LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	ΝA,	NI,
	NO, NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
	TJ, TM,	TN,	TR,	TT,	ΤZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
RW:	BW, GH,	GM,	ΚE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	ΤZ,	ŪG,	ZM,	ZW,	AM,
	AZ, BY,	KG,	ΚZ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
	EE, ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,
	SI, SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,
	SN, TD,	TG													
DE 1035	A1 20050421				DE 2	003-	1035	8822	20031216						
PRIORITY APPLN. INFO.:							;	DE 2	003-	1034	5724	A 20031001			
								DE 2	003-	1035	8822	7	A 2	0031	216
GI															

HO OH C1H

3 HC1

$$H_2C$$
 $H_2N$ 
 $CO$ 
 $NH$ 
 $CO$ 
 $NH$ 
 $CO$ 
 $NH$ 
 $CO$ 
 $NH$ 
 $CO$ 
 $Me$ 
 $OH$ 
 $OH$ 

AB Macrocyclic biphenyl-containing oligopeptide amides, e.g., (I), analogs of biphenomycin B, were prepared for use in the treatment and prevention of bacterial infections in humans and animals. The biphenyl-linked dipeptide was first prepared, beginning from salicaldehyde, in 12 steps, followed by peptide coupling with an appropriate amino acid and macrocyclization. The resulting intermediate was coupled with a suitable amine-containing reactant to give title compds. as free bases or salts. In in vitro tests against S. aureus strains, including S. aureus 133, I was effective at min. blood concns. of 4 μg/mL. I had IC50 values in transcription-translation

Absolute stereochemistry.

● HCl

RN 849814-36-4 CAPLUS

CN [1,1'-Biphenyl]-3,3'-dipropanoic acid,  $\alpha$ -amino-4,4'-bis(phenylmethoxy)- $\alpha$ '-[[(phenylmethoxy) carbonyl]amino]-,  $\alpha$ -methyl  $\alpha$ '-[2-(trimethylsilyl)ethyl] ester, monohydrochloride, ( $\alpha$ S, $\alpha$ 'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

### ● HCl

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS 2 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CAPLUS COPYRIGHT 2005 ACS on STN L18 ANSWER 2 OF 9

ACCESSION NUMBER:

2004:117114 CAPLUS

DOCUMENT NUMBER:

140:164239

TITLE:

Antibacterial ester macro cycles

INVENTOR(S):

Lampe, Thomas; Adelt, Isabelle; Beyer, Dieter; Brunner, Nina; Endermann, Rainer; Ehlert, Kerstin; Kroll, Hein-Peter; Von Nussbaum, Franz; Raddatz, Siegfried; Rudolph, Joachim; Schiffer, Guido;

Schumacher, Andreas Bayer AG, Germany

PATENT ASSIGNEE(S):

SOURCE:

Ger. Offen., 41 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

LANGUAGE:

Patent

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	PATENT NO.								-	APPL:								
	22 2020					A1 20040212 AA 20040212				DE 2	002-							
										20030718								
WO					A1 20040212 AM, AT, AU, AZ,													
	W:	ÆΕ,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NI,	NO,	ΝZ,	OM,	
		PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ТJ,	TM,	TN,	
		TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW				
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,	
		KG,	ΚZ,	MD,	RU,	ΤJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DΕ,	DK,	EE,	ES,	
		FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,	
		BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG	
EP	EP 1526896					A1 20050504				EP 2	003-	7662		20030718				
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK		
PRIORIT	Y APP	LN.	INFO	.:						DE 2	002-	1023	1	A 20020729				
							WO 2	003-	EP78.	24	1	W 2	0030	718				

OTHER SOURCE(S):

AB The present invention concerns compds., e.g. (I), procedures for their production, and pharmaceutical compns. containing them for use in the treatment of

Ι

bacterial infections of humans or animals. The biphenyl system was constructed beginning with salicylaldehyde, which was 5-iodinated, O-benzylated, and reduced to the hydroxymethyl derivative, which was then brominated, replacing the hydroxy group. This intermediate was reacted with di-Et 2-tert-butoxycarbonylaminomalonate, followed by a mono-decarboxylation, to give (D/L)-N-Boc-2'-benzyloxy-5'-iodophenylalanine (II), which was then resolved to give pure (S)-II (ee >99%); this was C-protected as the benzyl ester, and part was reacted with bis(pinacolato)diborane to give intermediate (III). A second portion of II was transformed to the N-Cbz-protected form, and the acid esterified with 2-trimethylsilyl-ethanol to give intermediate (IV). Intermediates III and IV were reacted to give the chiral N,C-protected biphenyl portion of I (V). In a sep. sequence, t-Bu 5-Cbz-2(S)-Boc-amino-4(R)hydroxypentanoate was used to prepare 4(R)-tBDMS-protected Boc-L-4-hydroxy-Ne-Cbz-ornithine, which was reacted with the Boc-deprotected V. Macrocyclization of the resulting intermediate consisted of activation of the second acid group as the pentafluorophenyl ester, and concurrent Boc-deprotection and cyclization to give the N',N", O,O'-protected I as its benzyl ester, which was deprotected/deesterified and re-esterified to give the Me or Et ester title compds. In in vitro tests against S. aureus 133 and B. catarrhalis M3, I was active at minimal blood concns. of 0.78 and 6.25  $\mu M$  resp.; I had IC50 values in transcription-translation tests against E. coli and S. aureus 133 of 0.2 and  $2.4-4.3 \mu M$ , resp.

#### IT 636594-74-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of antibacterial biphenomycin B ester analogs for use in human or veterinary medicine)

RN 636594-74-6 CAPLUS

CN [1,1'-Biphenyl]-3,3'-dipropanoic acid,  $\alpha$ -amino-4,4'-bis(phenylmethoxy)- $\alpha$ '-[[(phenylmethoxy)carbonyl]amino]-,  $\alpha$ -(phenylmethyl)  $\alpha$ '-[2-(trimethylsilyl)ethyl] ester, monohydrochloride, ( $\alpha$ S, $\alpha$ 'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

### ● HCl

L18 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

2003:1007003 CAPLUS

DOCUMENT NUMBER:

INVENTOR(S):

140:59934

TITLE:

Synthesis of cyclic peptide macrolides for use in the

treatment and prevention of bacterial infection Lampe, Thomas; Adelt, Isabelle; Beyer, Dieter;

Brunner, Nina; Endermann, Rainer; Ehlert, Kerstin; Kroll, Hein-Peter; Von Nussbaum, Franz; Raddatz, Siegfried; Rudolph, Joachim; Schiffer, Guido;

Schumacher, Andreas; Cancho-Grande, Yolanda; Michels,

Martin; Weigand, Stefan

PATENT ASSIGNEE(S):

Bayer Healthcare A.-G., Germany

SOURCE:

PCT Int. Appl., 190 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent German LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA'	rent 1	NO.			KINI	D :	DATE		į		ICAT:		DATE						
WO	WO 2003106480				A1		2003	1224	1	WO 2	003-	EP60.	20030610						
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,		
		co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,		
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,		
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NI,	NO,	NZ,	OM,		
							SC,												
		TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	zw							
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,		
		KG,	KZ,	MD,	RU,	TJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,		
		FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,		
		BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG		
DE	DE 10226921						2003	1224		DE 2	002-	1022	20020617						
CA	CA 2489454				AA		2004	1214	1	CA 2	003-	2489							
EP	EP 1515983		A1					EP 2	003-	7380	12								
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,		
							RO,												
BR	BR 2003011948																		
PRIORIT	Y APP	LN.	INFO	.:					DE 2002-10226921 A						A 2				

MARPAT 140:59934

HO 
$$CH_2$$
 OH  $CH_2$  OH  $CO-NH_2$ 

NH2

The invention relates to antibacterial amide macrocycles, e.g. (I), to AB methods for the production thereof, and to the use of the same for producing pharmaceuticals for the treatment and/or prophylaxis of illness, especially bacterial infections. Title compds. were synthesized beginning with salicylaldehyde, which was 5-iodinated, 0-protected, reduced to the hydroxymethyl, brominated on the CH2 group, and coupled with di-Et 2-tert-butoxycarbonylaminomalonate, which, after decarboxylation and deesterification, gave the (DL)-N-Boc-protected 2'-benzyloxy-5'-iodophenylalanine (II). II was resolved into its pure D- and L-enantiomers; the L-II was protected as the N-Cbz derivative, then esterified with 2-(trimethylsilyl)ethanol, then reacted with (III) (prepared from II and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane) to give biphenyl compound (IV). In a sep. reaction, (V) was prepared from the corresponding L-ornithine tert-Bu ester, the lactone opened and the alc. protected as the tert-butyldimethylsilyl derivative, and reacted with biphenyl IV, to give, after deprotection and amide formation, I as the dihydrochloride salt. In in vitro tests, using S. aureus, E. faecalis, B. catarrhalis, and E. coli strains, I had min. blood concentration effective ranges

Ι

of  $0.2-6.25 \mu M$ .

## IT 636594-74-6P 636594-97-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of biphenyl-containing cyclic peptide macrolides for use in the treatment and prevention of bacterial infection)

RN 636594-74-6 CAPLUS

CN [1,1'-Biphenyl]-3,3'-dipropanoic acid,  $\alpha$ -amino-4,4'-bis(phenylmethoxy)- $\alpha$ '-[[(phenylmethoxy)carbonyl]amino]-,  $\alpha$ -(phenylmethyl)  $\alpha$ '-[2-(trimethylsilyl)ethyl] ester, monohydrochloride, ( $\alpha$ S, $\alpha$ 'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

HC1

636594-97-3 CAPLUS RN

L-Phenylalanine, 3-[3'-[(2S)-3-oxo-2-[[(phenylmethoxy)carbonyl]amino]-3-[2-CN (trimethylsilyl) ethoxy[propyl]-4,4'-bis(phenylmethoxy)[1,1'-biphenyl]-3yl]-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS 5. RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

2003:345276 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER:

139:180323

Synthesis of the (S,S,S)-diastereomer of the TITLE:

15-membered biaryl ring system of RP 66453

Krenitsky, Paul J.; Boger, Dale L. AUTHOR(S):

Department of Chemistry and The Skaggs Institute for CORPORATE SOURCE:

Chemical Biology, The Scripps Research Institute, San Diego, CA, 92037, USA

Tetrahedron Letters (2003), 44(21), 4019-4022 SOURCE:

CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd. DOCUMENT TYPE: LANGUAGE:

Journal English

OTHER SOURCE(S):

CASREACT 139:180323

GΙ

AB This work reports the synthesis of the 15-membered biaryl ring I, which constitutes an appropriately functionalized AB ring system of RP 66453.

IT 579469-86-6P 622338-03-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of the (S,S,S)-diastereomer of the 15-membered biaryl ring system of RP 66453)

RN 579469-86-6 CAPLUS

CN L-Isoleucine, 3-[5'-[(2S)-2-amino-3-methoxy-3-oxopropyl]-3'-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2',6-dimethoxy[1,1'-biphenyl]-3-yl]-N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 622338-03-8 CAPLUS

CN [1,1'-Biphenyl]-3-propanoic acid, α-amino-5'-[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methoxymethoxy)propyl]-5-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2',6-dimethoxy-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

# Absolute stereochemistry.

21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

2002:211071 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 137:93981

Studies toward the total synthesis of RP-66453 TITLE:

AUTHOR(S): Boisnard, Sabine; Zhu, Jieping

CNRS, Institut de Chimie des Substances Naturelles, CORPORATE SOURCE:

Gif-sur-Yvette, 91198, Fr.

Tetrahedron Letters (2002), 43(14), 2577-2580 CODEN: TELEAY; ISSN: 0040-4039 SOURCE:

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:93981

GI

AB Synthesis of a bicyclic A-B-O-C ring system of RP-66453 (I), a neurotensine receptor antagonist, with an endo aryl-aryl and an endo aryl-aryl ether bond is described. An alternative synthetic strategy starting from the construction of functionalized B-O-C cycloisodityrosine unit is also detailed.

Ι

IT 351442-24-5

RL: RCT (Reactant); RACT (Reactant or reagent) (reaction of in the preparation of bicyclic A-B-O-C ring system of RP-66453)

RN 351442-24-5 CAPLUS

CN [1,1'-Biphenyl]-3,3'-dipropanoic acid, α-amino-α'-[[(1,1-dimethylethoxy)carbonyl]amino]-6'-methoxy-5,6-bis(1-methylethoxy)-,α-(1,1-dimethylethyl) α'-methyl ester, (αS,α'S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:381070 CAPLUS

DOCUMENT NUMBER: 135:137701

TITLE: Studies on the Total Synthesis of RP 66453: Synthesis

of Fully Functionalized 15-Membered Biaryl-Containing

Macrocycle

AUTHOR(S): Boisnard, Sabine; Carbonnelle, Anny-Claude; Zhu,

Jieping

CORPORATE SOURCE: Institut de Chimie des Substances Naturelles, CNRS,

Gif-sur-Yvette, 91198, Fr.

SOURCE: Organic Letters (2001), 3(13), 2061-2064

CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:137701

GI

AB Palladium-catalyzed Suzuki cross-coupling, Corey's enantioselective alkylation of glycine template, and macrolactamization are key steps in an efficient synthesis of the 15-membered macrocycle I, the A-B biaryl macrocyclic component of RP-66453 (II). Unfortunately, the cyclization of I by various methods (varying the base, the solvent and the temperature) did not

provide the desired macrocycle II.

IT 351442-24-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(total synthesis of the fully functionalized biaryl, macrocyclic component of RP-66453)

RN 351442-24-5 CAPLUS

CN [1,1'-Biphenyl]-3,3'-dipropanoic acid,  $\alpha$ -amino- $\alpha$ '-[{(1,1-dimethylethoxy)carbonyl]amino]-6'-methoxy-5,6-bis(1-methylethoxy)-,  $\alpha$ -(1,1-dimethylethyl)  $\alpha$ '-methyl ester, ( $\alpha$ S, $\alpha$ 'S)-

II

Absolute stereochemistry.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:445595 CAPLUS

DOCUMENT NUMBER: 125:137462

TITLE: N,N'-bisformyl dityrosine is an in vivo precursor of

the yeast ascospore wall

AUTHOR(S): Briza, Peter; Kalchhauser, Hermann; Pittenauer, Ernst;

Allmaier, Guenter; Breitenbach, Michael

CORPORATE SOURCE: Institut Genetik und Allemeine Biologie, Universitaet

Salzburg, Salzburg, A-5020, Austria

SOURCE: European Journal of Biochemistry (1996), 239(1),

124-131

CODEN: EJBCAI; ISSN: 0014-2956

PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

The amino acid, dityrosine, is a major component of he spore wall surface of the yeast Saccharomyces cerevisiae, where it is part of a highly cross-linked macromol. network of yet unknown chemical structure, consisting mostly of glucosamine, dityrosine and few other amino acids. Biosynthesis of the dityrosine moiety of this network consists of several steps, including the chemical modification of free L-tyrosine and the subsequent oxidative crosslinking of the modified tyrosine residues (catalyzed by a cytochrome P 450), leading to soluble dityrosine-containing spore wall precursors. We isolated, purified and characterized the dityrosine-containing precursor that appears late in spore wall synthesis and that is thought to be directly incorporated into the maturing spore wall. Chemical and spectroscopic analyses showed that this precursor is N,N'-bisformyl dityrosine. In addition, we identified a tyrosine-containing spore wall precursor as N-formyl tyrosine. The elucidation of the chemical structure of soluble spore wall precursors is crucial for the characterization of the function of the enzymes involved in maturation of the spore surface, e.g. by in vitro systems. A dityrosine-containing fragment, which was solubilized from mature spore walls by partial hydrolysis, was identified as N-formyl

dityrosine. Mature spore walls contain significant amts. of N-formyl dityrosine and N,N'-bisformyl dityrosine. This supports the assumption that the dityrosine-containing macromol. network on the spore surface has an unusual, nonpeptidic structure.

IT 179555-54-5P 179798-22-2P

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process)

(N,N'-bisformyl dityrosine is in vivo precursor of yeast ascospore wall)

RN 179555-54-5 CAPLUS

CN [1,1'-Biphenyl]-3,3'-dipropanoic acid,  $\alpha$ -amino- $\alpha$ '- (formylamino)-6,6'-dihydroxy-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 179798-22-2 CAPLUS

CN [1,1'-Biphenyl]-3,3'-dipropanoic acid,  $\alpha$ -amino- $\alpha$ -(formylamino)-6,6'-dihydroxy-, (R\*,S\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L18 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:559729 CAPLUS

DOCUMENT NUMBER: 115:159729

TITLE: The synthesis of biphenomycin B [Erratum to document

cited in CA114(25):247764b]

AUTHOR(S): Schmidt, Ulrich; Meyer, Regina; Leitenberger, Volker;

Lieberknecht, Albrecht; Griesser, Helmut

CORPORATE SOURCE: Inst. Org. Chem. Isotopenforsch., Univ. Stuttgart,

Stuttgart, 7000/80, Germany

SOURCE:

Journal of the Chemical Society, Chemical

Communications (1991), (10), 744 CODEN: JCCCAT; ISSN: 0022-4936

DOCUMENT TYPE: LANGUAGE:

Journal English

An error in the summary has been corrected Biphenomycin B is a highly potent

antibiotic against Gram-pos. bacteria, not Gram-neg. as reported. The

error was reflected in the abstract

ΙT 134038-83-8P

> RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and peptide coupling of, with hydroxyornithine derivative

(Erratum))

RN 134038-83-8 CAPLUS

[1,1'-Biphenyl]-3,3'-dipropanoic acid,  $\alpha$ -amino-4,4'-CN bis (phenylmethoxy)  $-\alpha'$  - [[(phenylmethoxy) carbonyl] amino] -,  $\alpha$ -(phenylmethyl)  $\alpha$ '-[2-(trimethylsilyl)ethyl] ester,

 $[S-(R^*,R^*)]-(9CI)$  (CA INDEX NAME)

#### Absolute stereochemistry.

L18 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

1991:247764 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 114:247764

TITLE: The synthesis of biphenomycin B

Journal

AUTHOR(S): Schmidt, Ulrich; Meyer, Regina; Leitenberger, Volker;

Lieberknecht, Albrecht; Griesser, Helmut

CORPORATE SOURCE: Inst. Org. Chem. Isotopenforsch., Univ. Stuttgart,

Stuttgart, 7000/80, Germany

Journal of the Chemical Society, Chemical SOURCE:

Communications (1991), (5), 275-7

CODEN: JCCCAT; ISSN: 0022-4936

DOCUMENT TYPE:

LANGUAGE:

English

OTHER SOURCE(S): CASREACT 114:247764

GT